^
Association details:
| Biomarker: | FGFR2-AFF4 fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Pemazyre (pemigatinib) (FGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
2622 / 12 - Combination AXL-FGFR inhibition as a therapeutic strategy in cholangiocarcinoma
Published date:
03/08/2022
Excerpt:
A CCA cell line was developed from PDX283, a patient-derived xenograft model from a surgically resected intrahepatic CCA with a FGFR2-AFF4 fusion....PDX283 was resistant to pemigatinib in short term viability assays at the maximal concentrations tested, with an IC50 > 10 μM. To understand the broader mechanisms of therapeutic resistance in CCA, phosphoproteomic evaluation of HuCCT1 cells was performed.
